supplementation in coronary heart disease

Not Applicable

• Conditions: Atherosclerotic Coronary Heart disease.; Atherosclerotic heart disease

• Registration Number: IRCT2017092836469N1
• Lead Sponsor: Vice Chancellor for research of Tarbiat Modares University, Faculty of medical science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

Men Diagnosed with Coronary heart patients
45-55 y of old
BMI (in kg/m2) of 25-35
No tobacco or alcohol consumption
free of any serious and life-threatening illness, Malignancy, Cancer, Diabetes, Autoimmune disease, Infectious diseases, Anemia and with no stone maker kidney or bladder
Subjects with no history of allergic reaction to beetroot or prickly pear
No changes in drug administration (patients only consume typically administered drugs for hypertension or dyslipidemia)
Subjects with no recent or current consumption of interventional supplements
Patients will be enrolled following an informed consent.

Exclusion Criteria

Myocardial Infarction
Strenuous exercise
Fasting
Allergic reactions
Any exposure or catch of infectious disease
Any side effect
Subjects with recent or current taking systemic medication (other than the usual drug for hypertension and dyslipidemia)
Patients with Failure to execute commands
Healthy subjects unwilling to consent

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sirtuin-1 gene. Timepoint: days: 0, 14, 28, 42, 56, 70, and after single dose consumption in part 2 of study. Method of measurement: expression measurement with Real-Time PCR.;Lectin-like oxidized low density lipoprotein receptor-1 gene. Timepoint: days: 0, 14, 28, 42, 56, 70, and after single dose consumption in part 2 of study. Method of measurement: expression measurement with Real-Time PCR.;Sirtuin-1 protein. Timepoint: days: 0, 14, 28, 42, 56, 70, and after single dose consumption in part 2 of study. Method of measurement: Concentration measurement with ELIZA.